FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Merrill Egorin

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Living Beings

Mouse

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Jianxia Guo; Robert A Parise; Elizabeth R Sharlow; Qiming Jane Wang; Peter Wipf; Jan H Beumer; Karla Bravo-Altamirano; Dana M Clausen; Merrill J Egorin; Julie L Eiseman
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.
Lionel D Lewis; Svetlana Markova; Howard L McLeod; Antonius A Miller; Kouros Owzar; Mark J Ratain; Robert R Bies; Merrill J Egorin; Chen Jiang; Deanna L Kroetz
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Robert A Parise; Bean N Anyang; Joseph M Covey; Merrill J Egorin; Julie L Eiseman; Jan H Beumer
Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Merrill Egorin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jianxia Guo; Robert A Parise; Elizabeth R Sharlow; Qiming Jane Wang; Peter Wipf; Jan H Beumer; Karla Bravo-Altamirano; Dana M Clausen; Merrill J Egorin; Julie L Eiseman
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.
Cancer chemotherapy and pharmacology 2013;71(2):331-44.
2013: Lionel D Lewis; Svetlana Markova; Howard L McLeod; Antonius A Miller; Kouros Owzar; Mark J Ratain; Robert R Bies; Merrill J Egorin; Chen Jiang; Deanna L Kroetz
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Pharmacogenetics and genomics 2013;23(1):29-33.
2013: Robert A Parise; Bean N Anyang; Joseph M Covey; Merrill J Egorin; Julie L Eiseman; Jan H Beumer
Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.
Cancer chemotherapy and pharmacology 2013;71(1):73-83.
2012: Michael J Pishvaian; Rebecca Slack; Sandy Strychor; Jan H Beumer; Ion Cotarla; John Deeken; Merrill J Egorin; Beth Elston; Kashif Firozvi; Marion L Hartley; Aiwu Ruth He; Jimmy Hwang; Eunice Y Koh; Minetta Liu; Shakun Malik; John L Marshall
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Cancer chemotherapy and pharmacology 2012;70(6):843-53.
2012: Karen E Mulder; Merrill J Egorin; Michael B Sawyer
Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib.
Investigational new drugs 2012;30(6):2400-2.
2012: Chadi Nabhan; K Tolzien; T V Valdez; Dana Villines; J D Bitran; Susan Lubawy; Merrill J Egorin; T M Lestingi; J H Beumer
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
British journal of cancer 2012;107(4):592-7.
2012: Eric A Sherer; David B Solit; Chandra P Belani; Merrill J Egorin; Percy S Ivy; Jeffrey A Lieberman; Stephen B Manuck; Stephen R Marder; Matthew F Muldoon; Bruce G Pollock; Mark E Sale; Howard I Scher; Robert R Bies
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
Journal of pharmacokinetics and pharmacodynamics 2012;39(4):393-414.
2012: Abdulateef O Aregbe; Chandra P Belani; Merrill J Egorin; Percy S Ivy; Suresh Ramalingam; Ramesh K Ramanathan; Howard I Scher; Eric A Sherer; David B Solit; Robert R Bies
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;70(1):201-5.
2012: Prithviraj Bose; A Dimitrios Colevas; Brenda W Cooper; W Douglas Figg; Merrill J Egorin; Jan H Beumer; Connie Honeycut; Chiyo K Imamura; James W Jacobberger; Judith E Karp; Omer N Koc; Emmanouil Kontopodis; Selina M Luger; Edward B Perkins; John D Roberts; Tammy Stefan; Martha D Wellons; Steven Grant
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Cancer chemotherapy and pharmacology 2012;69(6):1657-67.
2012: Gopa Iyer; Steven M Larson; Michael J Morris; Dana Elizabeth Rathkopf; Neal Rosen; Howard I Scher; Lawrence H Schwartz; Susan F Slovin; Tracy Curley; Anthony Delacruz; Merrill J Egorin; Glenn Heller; S Percy Ivy; Macaulay Steers; Qing Ye; David B Solit
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;69(4):1089-97.
2011: Ticiana B Leal; Heinz-Josef Lenz; Patricia M LoRusso; Sridhar Mani; James Mier; Angela Davies; Merrill J Egorin; Anne Hamilton; S Percy Ivy; Rachel Neuwirth; Ramesh K Ramanathan; Scot C Remick; John Sarantopoulos; Stephen Shibata; Chris H Takimoto; Karthik Venkatakrishnan; Lisa von Moltke; John J Wright; Daniel Mulkerin
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Cancer chemotherapy and pharmacology 2011;68(6):1439-47.
2011: Elisabeth Iljas Heath; Patricia M LoRusso; Suresh S Ramalingam; Manuel Valdivieso; Xiaofei Zhou; Tatiana Besse-Hamer; Fatima Cardoso; Merrill J Egorin; Teresa Has; Leila Alland; Ahmad Awada; Chandra P Belani
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
Investigational new drugs 2011;29(6):1426-31.
2011: Rajul K Jain; Candace S Johnson; Merrill J Egorin; Manuel Fernandez; Donald L Trump; Ramesh K Ramanathan
A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors.
Investigational new drugs 2011;29(6):1420-5.
2011: Jonathan Hebb; Caroline Rousseau; Raquel Aloyz; Lilian Amrein; Sarit Assouline; Stephen Caplan; Pierre Desjardins; Merrill J Egorin; Lawrence Panasci
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Cancer chemotherapy and pharmacology 2011;68(3):643-51.
2011: Anastasios Stathis; Sebastien J Hotte; Eric X Chen; Hal Hirte; Amit M Oza; Patricia Moretto; Sheila Webster; Anne Laughlin; Lee-Anne Stayner; Shauna McGill; Lisa Wang; Wen-jiang Zhang; Igor Espinoza-Delgado; Julianne L Holleran; Merrill J Egorin; Lillian L Siu
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(6):1582-90.
2011: Jan H Beumer; Julie L Eiseman; Judith A Gilbert; Julianne L Holleran; Archibong E Yellow-Duke; Dana M Clausen; David Z D'Argenio; Matthew M Ames; Pamela A Hershberger; Robert A Parise; Lihua Bai; Joseph M Covey; Merrill J Egorin
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Cancer chemotherapy and pharmacology 2011;67(2):421-30.
2011: Alberuni M Zamah; Marcelle I Cedars; Brian J Druker; Merrill J Egorin; Michael J Mauro; Kutluk Oktay; Mitchell P Rosen
Will imatinib compromise reproductive capacity?
The oncologist 2011;16(10):1422-7.
2011: Henry B Koon; Barbara Fingleton; Jeannette Y Lee; Julia T Geyer; Ethel Cesarman; Robert A Parise; Merrill J Egorin; Bruce J Dezube; David Aboulafia; Susan E Krown
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.
Journal of acquired immune deficiency syndromes (1999) 2011;56(1):64-8.
2010: Dana M Clausen; Jianxia Guo; Robert A Parise; Jan H Beumer; Merrill J Egorin; John Lazo; Edward V Prochownik; Julie L Eiseman
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
The Journal of pharmacology and experimental therapeutics 2010;335(3):715-27.
2010: Anjali Advani; Ramon Tiu; Yogen Saunthararajah; Jaroslaw Maciejewski; Edward A Copelan; Ronald Sobecks; Mikkael A Sekeres; Jennifer Bates; Mary Lynn Rush; Barbara Tripp; August Salvado; Elysa Noon; Matthew Howard; Tao Jin; Eric D Hsi; Merrill J Egorin; Kathleen Lim; Claudiu V Cotta; Courtney Price; Matt Kalaycio
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Leukemia research 2010;34(12):1622-6.
2010: Suresh S Ramalingam; Shivaani Kummar; John Sarantopoulos; Stephen Shibata; Patricia M LoRusso; Mara Yerk; Julianne Holleran; Yan Lin; Jan H Beumer; R Donald Harvey; S Percy Ivy; Chandra P Belani; Merrill J Egorin
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):4507-12.
2010: Julianne L Holleran; Robert A Parise; Archibong E Yellow-Duke; Merrill J Egorin; Julie L Eiseman; Joseph M Covey; Jan H Beumer
Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.
Journal of pharmaceutical and biomedical analysis 2010;52(5):714-20.
2010: Sakkaraiappan Ramalingam; R Donald Harvey; Nabil Saba; Taofeek K Owonikoko; John Kauh; Dong M Shin; Shi-Yong Sun; Sandra Strychor; Mourad Tighiouart; Merrill J Egorin; Haian Fu; Fadlo R Khuri
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
Cancer 2010;116(16):3903-9.
2010: Ulka Nitin Vaishampayan; Angelika Burger; Edward A Sausville; Lance K Heilbrun; Jing Li; Margit N Horiba; Merrill J Egorin; Percy Ivy; Simon Pacey; Patricia M LoRusso
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(14):3795-804.
2010: Marwan G Fakih; Gerald Fetterly; Merrill J Egorin; Josephia R Muindi; Igor Espinoza-Delgado; James Zwiebel; Alan Litwin; Julianne L Holleran; Kangsheng Wang; Robert B Diasio
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(14):3786-94.
2010: Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
British journal of haematology 2010;150(1):72-82.
2010: Ramesh K Ramanathan; Merrill J Egorin; Charles Erlichman; Scot C Remick; Suresh S Ramalingam; Cynthia Naret; Julianne L Holleran; Cynthia J Teneyck; S Percy Ivy; Chandra P Belani
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1520-6.
2010: Heidi Colville; Ryan Dzadony; Rebecca Kemp; Stephen Stewart; Herbert J Zeh; David L Bartlett; Julianne L Holleran; Kevin Schombert; Juliann E Kosovec; Merrill J Egorin; Jan H Beumer
In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion.
The Journal of extra-corporeal technology 2010;42(1):75-9.
2009: Courtney M Tate; Melissa L Fishel; Julianne L Holleran; Merrill J Egorin; David G Skalnik
Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.
DNA repair 2009;8(12):1411-23.
2009: Jan H Beumer; M Boisdron-Celle; William Clarke; Jodi B Courtney; Merrill J Egorin; Erick Gamelin; Rebecca L Harney; Catherine A Hammett-Stabler; Sandy Lepp; Yunying Li; Gregory D Lundell; Gwen McMillin; Gerard Milano; Salvatore J Salamone
Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer.
Therapeutic drug monitoring 2009;31(6):688-94.
2009: Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa De Angelis; Minesh Mehta; Emmanuelle di Tomaso; Jan Drappatz; Santosh kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Neuro-oncology 2009;11(6):853-60.
2009: Merrill J Egorin; Michael J Mauro; Jonathan Trent
Drug plasma monitoring in CML and GIST: A case-based discussion.
Clinical advances in hematology & oncology : H&O 2009;7(11):S1, S3-11.
2009: Pamela N Munster; Douglas C Marchion; S Thomas; Merrill J Egorin; S Minton; G Springett; J-H Lee; G Simon; A Chiappori; D Sullivan; Adil Daud
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
British journal of cancer 2009;101(7):1044-50.
2009: Merrill J Egorin; Dhvani D Shah; Susan Lubawy; Mara A Yerk; Kristin A Komazec; Leonard R Appleman; Robert L Redner; Brian M Miller; Jan H Beumer
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
British journal of clinical pharmacology 2009;68(3):370-4.
2009: Carolina Pavlovsky; Merrill J Egorin; Dhvani D Shah; Jan H Beumer; Silvia Rogel; Santiago Pavlovsky
Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
Pharmacotherapy 2009;29(9):1152-6.
2009: Sylvain Baruchel; Julia R Sharp; Ute Bartels; Juliette Hukin; Isaac Odame; C Portwine; Douglas Strother; Chris Fryer; Jacqueline Halton; Merrill J Egorin; Rui Manuel Reis; Olga Martinho; Diana Stempak; Cynthia Hawkins; Janet Gammon; Eric Bouffet
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
European journal of cancer (Oxford, England : 1990) 2009;45(13):2352-9.
2009: Ashraf Badros; Angelika Burger; Sunita Philip; Ruben Niesvizky; Sarah S Kolla; Olga Goloubeva; Carolynn Harris; James Zwiebel; John J Wright; Igor Espinoza-Delgado; Maria R Baer; Julianne L Holleran; Merrill J Egorin; Steven Grant
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5250-7.
2009: Robert A Parise; Merrill J Egorin; Susan Lubawy; Dhvani D Shah; Wei Zhou; Jan H Beumer
A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(20-21):1894-900.
2009: Yuichi Tange; Akihide Kondo; Merrill J Egorin; Barbara Mania-Farnell; Georgy M Daneriallis; Hiromichi Nakazaki; Simone T Sredni; Veena Rajaram; Stewart Goldman; Marcelo B Soares; Tadanori Tomita
Interstitial continuous infusion therapy in a malignant glioma model in rats.
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2009;25(6):655-62.
2009: Deric M Park; Dhvani D Shah; Merrill J Egorin; Jan H Beumer
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.
Journal of neuro-oncology 2009;93(2):279-83.
2009: David A Reardon; Merrill J Egorin; Annick Desjardins; James J Vredenburgh; Jan H Beumer; Theodore F Lagattuta; Sridharan Gururangan; James E Herndon; August J Salvado; Henry S Friedman
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Cancer 2009;115(10):2188-98.
2009: Marwan G Fakih; Lakshmi Pendyala; Gerald Fetterly; Karoli Toth; James A Zwiebel; Igor Espinoza-Delgado; Alan Litwin; Youcef M Rustum; Mary Ellen Ross; Julianne L Holleran; Merrill J Egorin
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3189-95.
2009: Jianxia Guo; Robert A Parise; Erin Joseph; Merrill J Egorin; John Lazo; Edward V Prochownik; Julie L Eiseman
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.
Cancer chemotherapy and pharmacology 2009;63(4):615-25.
2009: Herbert J Zeh; Charles K Brown; Matthew P Holtzman; Merrill J Egorin; Julianne L Holleran; Douglas M Potter; David L Bartlett
A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
Annals of surgical oncology 2009;16(2):385-94.
2008: Cara A Rabik; Melissa L Fishel; Julianne L Holleran; Kristen Kasza; Mark R Kelley; Merrill J Egorin; M Eileen Dolan
Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.
The Journal of pharmacology and experimental therapeutics 2008;327(2):442-52.
2008: Archie N Tse; David S Klimstra; Mithat Gonen; Manish A Shah; Tahir Sheikh; Rachel Sikorski; Richard Carvajal; Janet Mui; Caroll Tipian; Eileen O'Reilly; Ki Young Chung; ROBERT G MAKI; Robert Lefkowitz; Karen T Brown; Katia Manova-Todorova; Nian Wu; Merrill J Egorin; David P Kelsen; Gary K Schwartz
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6704-11.
2008: Robert A Parise; Mohammad Shawaqfeh; Merrill J Egorin; Jan H Beumer
Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;872(1-2):141-7.
2008: T Clark Gamblin; Merrill J Egorin; Eleanor G Zuhowski; Theodore F Lagattuta; Laurie L Herscher; Angelo Russo; Steven Libutti; H Richard Alexander; Robert L Dedrick; David L Bartlett
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Cancer chemotherapy and pharmacology 2008;62(4):647-53.
2008: Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Cancer chemotherapy and pharmacology 2008;62(3):457-64.
2008: William C Zamboni; Sandra Strychor; Erin Joseph; Robert A Parise; Merrill J Egorin; Julie L Eiseman
Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
Cancer chemotherapy and pharmacology 2008;62(3):417-26.
2008: Ronald J Bernardi; Lisa R Bomgaars; Elizabeth Fox; FRANK BALIS; Merrill J Egorin; Theodore F Lagattuta; Alberta Aikin; Patricia Whitcomb; Jamie L Renbarger; Frank S Lieberman; Stacey L Berg; Susan M Blaney
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.
Cancer chemotherapy and pharmacology 2008;62(2):355-61.
2008: Jan H Beumer; Robert A Parise; Edward M Newman; James Doroshow; Timothy W Synold; Heinz-Josef Lenz; Merrill J Egorin
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Cancer chemotherapy and pharmacology 2008;62(2):363-8.
2008: Jan H Beumer; Julie L Eiseman; Robert A Parise; Erin Joseph; Joseph M Covey; Merrill J Egorin
Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3529-35.
2008: Sakkaraiappan Ramalingam; Merrill J Egorin; Ramesh K Ramanathan; Scot C Remick; Rachel Sikorski; Theodore F Lagattuta; Gurkamal S Chatta; David M Friedland; Ronald G Stoller; Douglas M Potter; S Percy Ivy; Chandra P Belani
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3456-61.
2008: David A Reardon; Annick Desjardins; James J Vredenburgh; Sith Sathornsumetee; Jeremy Rich; Jennifer A Quinn; Theodore F Lagattuta; Merrill J Egorin; Sridharan Gururangan; Roger E McLendon; James E Herndon; Allan H Friedman; August J Salvado; Henry S Friedman
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Neuro-oncology 2008;10(3):330-40.
2008: Merrill J Egorin
Population pharmacokinetc/pharmacodynamic modeling of paclitaxel and carboplatin in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2517; author reply 2517-8.
2008: Joseph Gibbons; Merrill J Egorin; Ramesh K Ramanathan; Pingfu Fu; Daniel Mulkerin; Stephen Shibata; Chris H Takimoto; Sridhar Mani; Patricia M LoRusso; Jean L Grem; Anna Pavlick; Heinz-Josef Lenz; Susan M Flick; Sherrie Reynolds; Theodore F Lagattuta; Robert A Parise; Yanfeng Wang; Anthony J Murgo; S Percy Ivy; Scot C Remick
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):570-6.
2008: Ramesh K Ramanathan; Merrill J Egorin; Chris H Takimoto; Scot C Remick; James Doroshow; Patricia M LoRusso; Daniel Mulkerin; Jean L Grem; Anne Hamilton; Anthony J Murgo; Douglas M Potter; Chandra P Belani; Michael J Hayes; Bin Peng; S Percy Ivy
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):563-9.
2008: Robert A Parise; Jan H Beumer; Cyrous O Kangani; Julianne L Holleran; Julie L Eiseman; Nicola F Smith; Joseph M Covey; Susan P Perrine; Merrill J Egorin
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;862(1-2):168-74.
2008: Juliann E Kosovec; Merrill J Egorin; Susanna Gjurich; Jan H Beumer
Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2008;22(2):224-30.
2007: Yaqoob Ali; Yong Lin; Mecide M Gharibo; Murugesan K Gounder; Mark N Stein; Theodore F Lagattuta; Merrill J Egorin; Eric H Rubin; Elizabeth Poplin
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5876-82.
2007: Jianxia Guo; Robert A Parise; Erin Joseph; Jing Lan; Su-Shu Pan; Beomjun Joo; Merrill J Egorin; Peter Wipf; John Lazo; Julie L Eiseman
Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).
Anticancer research 2007;27(5A):3067-73.
2007: Carolyn Blasdel; Merrill J Egorin; Theodore F Lagattuta; Brian J Druker; Michael W N Deininger
Therapeutic drug monitoring in CML patients on imatinib.
Blood 2007;110(5):1699-701; author reply 1701.
2007: Chris H Takimoto; Martin A Graham; Graham Lockwood; Chee M Ng; Andrew Goetz; Dennis Greenslade; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; Timothy W Synold; James Doroshow; Anne Hamilton; Daniel Mulkerin; Percy Ivy; Merrill J Egorin; Jean L Grem
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4832-9.
2007: Sakkaraiappan Ramalingam; Robert A Parise; Ramesh K Ramanathan; Ramesh K Ramananthan; Theodore F Lagattuta; Lori A Musguire; Ronald G Stoller; Douglas M Potter; Athanassios Argiris; James A Zwiebel; Merrill J Egorin; Chandra P Belani
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3605-10.
2007: Lionel D Lewis; Antonius A Miller; Gary Rosner; Jonathan E Dowell; Manuel Valdivieso; Mary Relling; Merrill J Egorin; Robert R Bies; Donna Hollis; Ellis G Levine; Gregory A Otterson; Frederick Millard; Mark J Ratain
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3302-11.
2007: Julie L Eiseman; Jianxia Guo; Ramesh K Ramanathan; Chandra P Belani; David B Solit; Howard I Scher; S Percy Ivy; Eleanor G Zuhowski; Merrill J Egorin
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2121-7.
2007: M A Russell; M W Carpenter; M S Akhtar; T F Lagattuta; Merrill J Egorin
Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
Journal of perinatology : official journal of the California Perinatal Association 2007;27(4):241-3.
2007: Rochelle Bagatell; Lia Gore; Merrill J Egorin; Richard Ho; Glenn Heller; Nichole Boucher; Eleanor G Zuhowski; James A Whitlock; Stephen P Hunger; Aru Narendran; Howard M Katzenstein; Robert J Arceci; Jessica Boklan; Cynthia E Herzog; Luke Whitesell; S Percy Ivy; Tanya M Trippett
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1783-8.
2007: David B Solit; S Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J Morris; Susan F Slovin; W Kevin Kelly; Anthony Delacruz; Tracy Curley; Glenn Heller; Steven M Larson; Lawrence H Schwartz; Merrill J Egorin; Neal Rosen; Howard I Scher
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1775-82.
2007: Ramesh K Ramanathan; Merrill J Egorin; Julie L Eiseman; Sakkaraiappan Ramalingam; David M Friedland; Sanjiv S Agarwala; S Percy Ivy; Douglas M Potter; Gurkamal S Chatta; Eleanor G Zuhowski; Ronald G Stoller; Cynthia Naret; Jianxia Guo; Chandra P Belani
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1769-74.
2007: Parisa Sinai; Rance E Berg; J Marshall Haynie; Merrill J Egorin; Robert L Ilaria; James Forman
Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(4):2028-37.
2007: Kathleen Mulligan; Robert Zackin; Jamie H Von Roenn; Margaret A Chesney; Merrill J Egorin; Fred R Sattler; Constance A Benson; Tun Liu; Triin Umbleja; Sharon Shriver; Richard J Auchus; Morris Schambelan
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
The Journal of clinical endocrinology and metabolism 2007;92(2):563-70.
2007: Robert A Parise; Merrill J Egorin; Julie L Eiseman; Erin Joseph; Joseph M Covey; Jan H Beumer
Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(13):1991-7.
2007: Sridhar Mani; Hayley M McDaid; A Grossman; Franco Muggia; SANJAY GOEL; T Griffin; D Colevas; Susan B. Horwitz; Merrill J Egorin
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):190-5.
2006: Jan H Beumer; Julie L Eiseman; Robert A Parise; Erin Joseph; Julianne L Holleran; Joseph M Covey; Merrill J Egorin
Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7483-91.
2006: Robert A Parise; Merrill J Egorin; Beatriz Kanterewicz; Mohammed Taimi; Martin Petkovich; April M Lew; Samuel S Chuang; Mark Nichols; Talal El-Hefnawy; Pamela A Hershberger
CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer.
International journal of cancer. Journal international du cancer 2006;119(8):1819-28.
2006: Jan H Beumer; Erin Joseph; Merrill J Egorin; Robert S Parker; David Z D'Argenio; Joseph M Covey; Julie L Eiseman
A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5826-33.
2006: Zejia Yang; Lisa Schumaker; Merrill J Egorin; Eleanor G Zuhowski; Zhongmin Guo; Kevin J Cullen
Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5817-25.
2006: William C Zamboni; Ramesh K Ramanathan; howard mcleod; Sridhar Mani; Douglas M Potter; Sandra Strychor; Lauren J Maruca; Cristi R King; Laura L Jung; Robert A Parise; Merrill J Egorin; Todd A Davis; Sharon Marsh
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Investigational new drugs 2006;24(5):393-401.
2006: Robert A Parise; Julianne L Holleran; Jan H Beumer; Sakkaraiappan Ramalingam; Merrill J Egorin
A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;840(2):108-15.
2006: Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Patricia Dahia; Yanfeng Wang; Bin Peng; Lauren E Abrey; Jeffrey Raizer; Timothy F Cloughesy; Karen Fink; Mark Gilbert; Susan Chang; Larry Junck; David Schiff; Frank Lieberman; Howard A Fine; Minesh Mehta; H Ian Robins; Lisa De Angelis; Morris D Groves; Vinay K Puduvalli; Victor Levin; Charles Conrad; Elizabeth A Maher; Kenneth Aldape; Michael Hayes; Laurie Letvak; Merrill J Egorin; Renaud Capdeville; Richard S. Kaplan; Anthony J Murgo; Charles D Stiles; Michael D Prados
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4899-907.
2006: Jan H Beumer; James J Natale; Theodore F Lagattuta; Anastasios Raptis; Merrill J Egorin
Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
Pharmacotherapy 2006;26(7):903-7.
2006: Edgar Faber; Jitka Nausová; Marie Jarosová; Merrill J Egorin; Milena Holzerová; Sárka Rozmanová; Ivana Maresová; Vladimír Divoký; Karel Indrák
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Leukemia & lymphoma 2006;47(6):1082-90.
2006: Mark J Ratain; Antonius A Miller; howard mcleod; Alan P Venook; Merrill J Egorin; Richard L Schilsky
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3612s-6s.
2006: Phillip H Abbosh; John S Montgomery; Jason A Starkey; Milos Novotny; Eleanor G Zuhowski; Merrill J Egorin; Annie P Moseman; Adam Golas; Kate M Brannon; Curtis Balch; Hui-Ming (Tim) Huang; Kenneth P Nephew
Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Cancer research 2006;66(11):5582-91.
2006: William C Zamboni; SANJAY GOEL; Tahir Iqbal; Robert A Parise; Sandra Strychor; Trisha V W Repinski; Merrill J Egorin; Sridhar Mani
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Cancer chemotherapy and pharmacology 2006;57(5):631-9.
2006: Stuart M Lichtman; Donna Hollis; Antonius A Miller; Gary Rosner; Chris A Rhoades; Eric P Lester; Frederick Millard; John Byrd; Stephen A Cullinan; D Marc Rosen; Robert A Parise; Mark J Ratain; Merrill J Egorin
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1846-51.
2006: Ramesh K Ramanathan; Marwan G Fakih; Sridhar Mani; Melvin Deutsch; Raymond P Perez; Mark A Ritter; Julie L Eiseman; S Percy Ivy; Donald L Trump; Chandra P Belani; Robert A Parise; Douglas M Potter; Merrill J Egorin
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Cancer chemotherapy and pharmacology 2006;57(4):465-74.
2006: Jason W Brown; Neil A Christie; Carol Evans; Merrill J Egorin
Case 4. Pulmonary stent migration and ingestion in a lung cancer patient.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1478-9.
2006: Jan H Beumer; Erin Joseph; Merrill J Egorin; Joseph M Covey; Julie L Eiseman
Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;831(1-2):147-55.
2006: Merrill J Egorin
The effects of organ dysfunction on drug dosing.
Clinical advances in hematology & oncology : H&O 2006;4(2):116-8.
2005: David A Reardon; Merrill J Egorin; Jennifer A Quinn; Jeremy Rich; Jeremy N Rich; Sridharan Gururangan; Idharan Gururangan; James J Vredenburgh; Annick Desjardins; Sith Sathornsumetee; James M Provenzale; James E Herndon; Jeannette M Dowell; Michael A Badruddoja; Roger E McLendon; Theodore F Lagattuta; Kimberly P Kicielinski; Gregor Dresemann; John H Sampson; Allan H Friedman; August J Salvado; Henry S Friedman
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9359-68.
2005: Elizabeth R Glaze; Amy L Lambert; Adaline C Smith; John G Page; William D Johnson; David L McCormick; Alan P Brown; Barry S Levine; Joseph M Covey; Merrill J Egorin; Julie L Eiseman; Julianne L Holleran; Edward A Sausville; Joseph E Tomaszewski
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Cancer chemotherapy and pharmacology 2005;56(6):637-47.
2005: Nikia A Laurie; Jonathan Gray; Jiakun Zhang; Mark Leggas; Mary Relling; Merrill J Egorin; Clinton Stewart; Michael A Dyer
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7569-78.
2005: Bernard J Komoroski; Robert A Parise; Merrill J Egorin; Stephen C Strom; Raman Venkataramanan
Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6972-9.
2005: William C Zamboni; Laura L Jung; Merrill J Egorin; Deborah R Hamburger; Erin Joseph; Ruzhi Jin; Sandra Strychor; Ramesh K Ramanathan; Julie L Eiseman
Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4867-74.
2005: V Koneti Rao; Turid Knutsen; Thomas Ried; Danny Wangsa; Bernard Mike Flynn; Gregory Langham; Merrill J Egorin; Diane Cole; FRANK BALIS; Seth M Steinberg; Susan Bates; Tito Fojo
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Mutation research 2005;583(2):105-19.
2005: Julianne L Holleran; Robert A Parise; Erin Joseph; Julie L Eiseman; Joseph M Covey; Elizabeth R Glaze; Aleksander V. Lyubimov; Ya-Fei Chen; David Z D'Argenio; Merrill J Egorin
Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3862-8.
2005: Ramesh K Ramanathan; Donald L Trump; Julie L Eiseman; Chandra P Belani; Sanjiv S Agarwala; Eleanor G Zuhowski; Jing Lan; Douglas M Potter; S Percy Ivy; Sakkaraiappan Ramalingam; Adam Brufsky; Michael K K Wong; Susan Tutchko; Merrill J Egorin
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3385-91.
2005: Ramesh K Ramanathan; Sakkaraiappan Ramalingam; Merrill J Egorin; Chandra P Belani; Douglas M Potter; Marwan G Fakih; Laura L Jung; Sandra Strychor; Samuel A Jacobs; David M Friedland; Dong M Shin; Gurkamal S Chatta; Susan Tutchko; William C Zamboni
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2005;55(4):354-60.
2005: Melissa L Fishel; Michael P Gamcsik; Shannon M Delaney; Eleanor G Zuhowski; Veronica M Maher; Theodore Karrison; Robert C Moschel; Merrill J Egorin; M Eileen Dolan
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.
Cancer chemotherapy and pharmacology 2005;55(4):333-42.
2005: John R Murren; Manuel Modiano; Shivaani Kummar; Caroline Clairmont; Merrill J Egorin; Edward Chu; Mario Sznol
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
Investigational new drugs 2005;23(2):123-35.
2005: Xueyu Chen; Robert R Bies; Ramesh K Ramanathan; Eleanor G Zuhowski; Donald L Trump; Merrill J Egorin
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2005;55(3):237-43.
2005: Henry B Koon; Glenn J Bubley; Liron Pantanowitz; David Masiello; Brad Smith; Katherine Crosby; Jo Ann Proper; Will Weeden; Thomas E Miller; Pamela Chatis; Merrill J Egorin; Steven R Tahan; Bruce J Dezube
Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(5):982-9.
2005: Julie L Eiseman; Jing Lan; Theodore F Lagattuta; Deborah R Hamburger; Erin Joseph; Joseph M Covey; Merrill J Egorin
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
Cancer chemotherapy and pharmacology 2005;55(1):21-32.
2005: Melissa L Fishel; David R Newell; Roger J Griffin; Richard Davison; Lan-Zhen Wang; Nicola J Curtin; Eleanor G Zuhowski; Kristen Kasza; Merrill J Egorin; Robert C Moschel; M Eileen Dolan
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
The Journal of pharmacology and experimental therapeutics 2005;312(1):206-13.
2004: Antonius A Miller; Gary Rosner; Merrill J Egorin; Donna Hollis; Stuart M Lichtman; Mark J Ratain
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8325-31.
2004: Laura L Jung; Ramesh K Ramanathan; Merrill J Egorin; Ruzhi Jin; Chandra P Belani; Douglas M Potter; Sandra Strychor; Donald L Trump; Christine M Walko; Marwan G Fakih; William C Zamboni
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Cancer chemotherapy and pharmacology 2004;54(6):487-96.
2004: Robert A Parise; Barney R Sparrow; John W Merrill; Irma M Grossi; Joseph M Covey; James O Peggins; Merrill J Egorin
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;810(1):35-40.
2004: Julie L Eiseman; Clive Brown-Proctor; Paul E Kinahan; Jerry M Collins; Lawrence W Anderson; Erin Joseph; Deborah R Hamburger; Su-Shu Pan; Chester A Mathis; Merrill J Egorin; Raymond W Klecker
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6669-76.
2004: Reginald F Frye; Sara M Fitzgerald; Theodore F Lagattuta; Matthew W Hruska; Merrill J Egorin
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Clinical pharmacology and therapeutics 2004;76(4):323-9.
2004: Sakkaraiappan Ramalingam; Theodore F Lagattuta; Merrill J Egorin; Michael J Hayes; Ramesh K Ramanathan
Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.
Pharmacotherapy 2004;24(9):1232-5.
2004: Katherine Warren; Anne Gervais; Alberta Aikin; Merrill J Egorin; FRANK BALIS
Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Cancer chemotherapy and pharmacology 2004;54(3):206-12.
2004: William C Zamboni; Laura L Jung; Merrill J Egorin; Douglas M Potter; David M Friedland; Chandra P Belani; Sanjiv S Agarwala; Michael M W Wong; Marwan G Fakih; Donald L Trump; Ruzhi Jin; Sandra Strychor; Michael Vozniak; Monica Troetschel; Ramesh K Ramanathan
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5058-64.
2004: Nicholas C Wolff; Dwight E Randle; Merrill J Egorin; John D Minna; Robert L Ilaria
Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3528-34.
2004: Julianne L Holleran; Julien Fourcade; Merrill J Egorin; Julie L Eiseman; Robert A Parise; Steven M Musser; Kevin D White; Joseph M Covey; Gerald L Forrest; Su-Shu Pan
In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(5):490-6.
2004: Kathleen Neville; Robert A Parise; Patrick Thompson; Alexander Aleksic; Merrill J Egorin; FRANK BALIS; Leticia McGuffey; Cynthia McCully; Stacey L Berg; Susan M Blaney
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2525-9.
2004: William C Zamboni; Anne C Gervais; Merrill J Egorin; Jan H M Schellens; Eleanor G Zuhowski; Dick Pluim; Erin Joseph; Deborah R Hamburger; Peter Working; Gail T Colbern; Margaret E Tonda; Douglas M Potter; Julie L Eiseman
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Cancer chemotherapy and pharmacology 2004;53(4):329-36.
2004: Roger S Day; Brenda K Manning; Denise Garrott; Adam Brufsky; Joseph Baar; Merrill J Egorin; William E Shirey; Charles Friedman
Evaluation of the OncoTCap (Oncology Thinking Cap) simulation in teaching medical students about clinical trials: some successes and some surprises.
Journal of cancer education : the official journal of the American Association for Cancer Education 2004;19(3):149-55.
2003: Julianne L Holleran; Merrill J Egorin; Eleanor G Zuhowski; Robert A Parise; Steven M Musser; Su-Shu Pan
Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media.
Analytical biochemistry 2003;323(1):19-25.
2003: SANJAY GOEL; A Bulgaru; Howard Hochster; Scott Wadler; William C Zamboni; Merrill J Egorin; Percy Ivy; L Leibes; Franco Muggia; Graham Lockwood; E Harvey; G Renshaw; Sridhar Mani
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1682-7.
2003: Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill J Egorin; Dennis Greenslade; Andrew Goetz; Jean L Grem
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
Seminars in oncology 2003;30(4 Suppl 15):20-5.
2003: Steven M Musser; Merrill J Egorin; Eleanor G Zuhowski; Deborah R Hamburger; Robert A Parise; Joseph M Covey; Kevin D White; Julie L Eiseman
Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
Cancer chemotherapy and pharmacology 2003;52(2):139-46.
2003: Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill J Egorin; Barbara Schuler; Dennis Greenslade; Andrew Goetz; Ronald Knight; Rebecca Thomas; Brian P Monahan; William Dahut; Jean L Grem
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2664-72.
2003: Robert A Parise; Ramesh K Ramanathan; Michael J Hayes; Merrill J Egorin
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;791(1-2):39-44.
2003: Melissa L Fishel; Shannon M Delaney; Lindsay D Friesen; Ryan J Hansen; Eleanor G Zuhowski; Robert C Moschel; Merrill J Egorin; M Eileen Dolan
Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.
Molecular cancer therapeutics 2003;2(7):633-40.
2003: Nicholas C Wolff; James A Richardson; Merrill J Egorin; Robert L Ilaria
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
Blood 2003;101(12):5010-3.
2003: Lu Xu; Julie L Eiseman; Merrill J Egorin; David Z D'Argenio
Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
Journal of pharmacokinetics and pharmacodynamics 2003;30(3):185-219.
2003: Wallace Akerley; James E Herndon; Merrill J Egorin; Alan P Lyss; Hedy L Kindler; Dianne M Savarese; Carol A Sherman; D Marc Rosen; Donna Hollis; Mark J Ratain; Mark R Green
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Cancer 2003;97(10):2480-6.
2003: Menachem Laufer; Sakkaraiappan Ramalingam; Mark P Schoenberg; Mary Ellen Haisfield-Wolf; Eleanor G Zuhowski; Irene N Trueheart; Mario A Eisenberger; Ofer Nativ; Merrill J Egorin
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):697-703.
2003: Charles Rudin; Zejia Yang; Lisa Schumaker; David J VanderWeele; Kenneth A Newkirk; Merrill J Egorin; Eleanor G Zuhowski; Kevin J Cullen
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
Cancer research 2003;63(2):312-8.
2003: Merrill J Egorin
Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):182-3.
2003: Robert A Parise; Ramesh K Ramanathan; William C Zamboni; Merrill J Egorin
Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;783(1):231-6.
2003: Tomasz M Beer; Kristine M Eilers; Mark Garzotto; Merrill J Egorin; Bruce A Lowe; W David Henner
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):123-8.
2002: Josephia R Muindi; Yibing Peng; Douglas M Potter; Pamela A Hershberger; Jil S Tauch; Mary Jo Capozzoli; Merrill J Egorin; Candace S Johnson; Donald L Trump
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.
Clinical pharmacology and therapeutics 2002;72(6):648-59.
2002: Theodore F Logan; Fayega Jadali; Merrill J Egorin; Mark Mintun; Donald Sashin; William Gooding; Yong Choi; Harry Bishop; Donald L Trump; Diane Gardner; John Kirkwood; Daniel Vlock; Candace Johnson
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial.
Cancer chemotherapy and pharmacology 2002;50(6):433-44.
2002: William C Zamboni; Anne C Gervais; Merrill J Egorin; Jan H M Schellens; Deborah R Hamburger; Brian J Delauter; Amy Grim; Eleanor G Zuhowski; Erin Joseph; Dick Pluim; Douglas M Potter; Julie L Eiseman
Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2992-9.
2002: Khalid Matin; Merrill J Egorin; Michael F Ballesteros; David C Smith; Barry C Lembersky; Roger S Day; Candace S Johnson; Donald L Trump
Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.
Cancer chemotherapy and pharmacology 2002;50(3):179-85.
2002: Pamela A Hershberger; Terence F Mcguire; Wei-Dong Yu; Eleanor G Zuhowski; Jan H M Schellens; Merrill J Egorin; Donald L Trump; Candace S Johnson
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.
Molecular cancer therapeutics 2002;1(10):821-9.
2002: Merrill J Egorin; Eleanor G Zuhowski; Cynthia M McCully; Susan M Blaney; Jody Z Kerr; Stacey L Berg; FRANK BALIS
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2437-42.
2002: Ahmad Hashash; D Lynn Kirkpatrick; Merrill J Egorin; Lawrence Block; John Lazo
Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;768(2):239-46.
2002: Ian F Tannock; Carol M Lee; Jonathon K Tunggal; David S M Cowan; Merrill J Egorin
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):878-84.
2002: Merrill J Egorin; Theodore F Lagattuta; Deborah R Hamburger; Joseph M Covey; Kevin D White; Steven M Musser; Julie L Eiseman
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Cancer chemotherapy and pharmacology 2002;49(1):7-19.
2002: A H Calvert; Merrill J Egorin
Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies.
European journal of cancer (Oxford, England : 1990) 2002;38(1):11-6.
2001: K P Stecklair; Deborah R Hamburger; Merrill J Egorin; Robert A Parise; Joseph M Covey; Julie L Eiseman
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Cancer chemotherapy and pharmacology 2001;48(5):375-82.
2001: Ian N Olver; Margaret L J Davy; D Lüftner; S H Park; Merrill J Egorin; A Ellis; L Webster
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer.
Cancer chemotherapy and pharmacology 2001;48(2):109-14.
2001: William C Zamboni; David Z D'Argenio; C F Stewart; Thomas J MacVittie; Brian J Delauter; Ann Farese; Douglas M Potter; N M Kubat; D Tubergen; Merrill J Egorin
Pharmacodynamic model of topotecan-induced time course of neutropenia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2301-8.
2001: Jody Z Kerr; Stacey L Berg; Robert Dauser; Jed Nuchtern; Merrill J Egorin; Leticia McGuffey; Alexander Aleksic; Susan Blaney
Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Cancer chemotherapy and pharmacology 2001;47(5):411-4.
2001: Merrill J Egorin; Eleanor G Zuhowski; DM Rosen; DL Sentz; Joseph M Covey; Julie L Eiseman
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Cancer chemotherapy and pharmacology 2001;47(4):291-302.
2001: David I Rosenthal; Jason H Lee; Robert J Sinard; Denise Yardley; Mitchell Machtay; D M Rosen; Merrill J Egorin; Randal S Weber; Gregory S Weinstein; Ara A Chalian; L K Miller; Eugene P Frenkel; David P Carbone
Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1363-73.
2001: William C Zamboni; Diana Lüftner; Merrill J Egorin; M Schweigert; O Sezer; T Richter; J J Natale; K Possinger
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(1):119-22.
2001: Kyriakos P Papadopoulos; Merrill J Egorin; M Huang; Andrea B Troxel; Eliaz Kaufman; Casilda Balmaceda; Linda Vahdat; Charles Hesdorffer
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Cancer chemotherapy and pharmacology 2001;47(1):45-50.
2000: Robert A Parise; D R Miles; Merrill J Egorin
Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2000;749(2):145-52.
2000: A Patnaik; E Warner; M Michael; Merrill J Egorin; M J Moore; Lillian L Siu; Paula M Fracasso; S Rivkin; I Kerr; Litchman Manuel; Amit Oza
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(21):3677-89.
2000: Merrill J Egorin
Adenosine triphosphate-binding cassette proteins and bioavailability: "we can pump you up (or out)".
Journal of the National Cancer Institute 2000;92(20):1628-9.
2000: Brian J Delauter; Ramesh K Ramanathan; Merrill J Egorin; Lori Stover; Eleanor G Zuhowski; W Plunkett; William C Zamboni
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Pharmacotherapy 2000;20(10):1204-7.
2000: William C Zamboni; Merrill J Egorin; David A Van Echo; Roger S Day; Barry Meisenberg; Sandra E Brooks; L Austin Doyle; N N Nemieboka; J M Dobson; Nancy Tait; Katherine Tkaczuk
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(18):3288-94.
2000: John R Murren; Susan A DiStasio; Aurelio Lorico; Anne McKeon; E G Zuhowski; Merrill J Egorin; Alan C Sartorelli; Germana Rappa
Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.
Cancer journal (Sudbury, Mass.) 2000;6(4):256-65.
2000: K B Ain; Merrill J Egorin; P A DeSimone
Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.
Thyroid : official journal of the American Thyroid Association 2000;10(7):587-94.
2000: Alan P Venook; Merrill J Egorin; Gary Rosner; Donna Hollis; Sridhar Mani; M Hawkins; John Byrd; R Hohl; D Budman; N J Meropol; Mark J Ratain
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2780-7.
2000: Mohan Suntharalingam; ML Haas; BA Conley; Merrill J Egorin; S Levy; S Sivasailam; JOSEPH HERMAN; M C Jacobs; William C Gray; Robert A Ord; Joseph Aisner; David A Van Echo
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
International journal of radiation oncology, biology, physics 2000;47(1):49-56.
2000: Paula M Fracasso; Peter Westervelt; Carole L Fears; DM Rosen; Eleanor G Zuhowski; L A Cazenave; Litchman Manuel; Merrill J Egorin; P Westerveldt; C A Fears
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1124-34.
2000: Katherine Tkaczuk; William C Zamboni; Nancy Tait; Barry Meisenberg; L Austin Doyle; Martin J Edelman; Petr Hausner; Merrill J Egorin; David A Van Echo
Phase I study of docetaxel and topotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2000;46(6):442-8.
2000: Leslie L Muldoon; Michael A Pagel; RA Kroll; RE Brummett; Nancy D Doolittle; E G Zuhowski; Merrill J Egorin; Edward A Neuwelt
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):309-15.
1999: Joseph A Sparano; James Speyer; William J Gradishar; Leonard Liebes; R Sridhara; S Mendoza; David Fry; Merrill J Egorin
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):880-6.
1999: Chandra P Belani; C M Kearns; Eleanor G Zuhowski; K Erkmen; D Hiponia; D Zacharski; C Engstrom; Ramesh K Ramanathan; Mary Jo Capozzoli; Joseph Aisner; Merrill J Egorin
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):676-84.
1999: Merrill J Egorin; Eleanor G Zuhowski; DL Sentz; J M Dobson; PS Callery; Julie L Eiseman
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
Cancer chemotherapy and pharmacology 1999;44(4):283-94.
1999: Merrill J Egorin; Zhi-Min Yuan; DL Sentz; K Plaisance; Julie L Eiseman
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.
Cancer chemotherapy and pharmacology 1999;43(6):445-53.
1999: MA Steller; Merrill J Egorin; Edward L Trimble; David L Bartlett; E G Zuhowski; H Richard Alexander; Robert L Dedrick
A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Cancer chemotherapy and pharmacology 1999;43(2):106-14.
1998: Rogerio Lilenbaum; Antonius A Miller; G Batist; Stephen A Bernard; Donna Hollis; Gary Rosner; Merrill J Egorin; Richard L Schilsky; M J Ratain
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3302-9.
1998: R Sridhara; Mario A Eisenberger; Victoria Sinibaldi; L M Reyno; Merrill J Egorin
Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1998;7(7):631-4.
1998: Merrill J Egorin; DM Rosen; J H Wolff; PS Callery; Steven M Musser; Julie L Eiseman
Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
Cancer research 1998;58(11):2385-96.
1998: Alan P Venook; Merrill J Egorin; Gary Rosner; T D Brown; Thierry jahan; G Batist; R Hohl; D Budman; M J Ratain; C M Kearns; R L Schilsky
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1811-9.
1998: N R Bachur; L Lun; P M Sun; C M Trubey; E E Elliott; Merrill J Egorin; Linda H Malkas; Robert Hickey
Anthracycline antibiotic blockade of SV40 T antigen helicase action.
Biochemical pharmacology 1998;55(7):1025-34.
1998: Michael Glantz; Bernard F Cole; Lawrence D Recht; Wallace Akerley; P Mills; S Saris; F Hochberg; P Calabresi; Merrill J Egorin
High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1561-7.
1998: BA Conley; Merrill J Egorin; Nancy Tait; DM Rosen; Edward A Sausville; George J Dover; R J Fram; David A Van Echo
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):629-34.
1998: Merrill J Egorin; DM Rosen; R Sridhara; Lyle Sensenbrenner; Michele Cottler-Fox
Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):610-5.
1998: Merrill J Egorin
Overview of recent topics in clinical pharmacology of anticancer agents.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S22-30.
1997: Richard Hafner; Jonathan A Cohn; D J Wright; N E Dunlap; Merrill J Egorin; M E Enama; K Muth; C A Peloquin; N Mor; LB Heifets
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.
American journal of respiratory and critical care medicine 1997;156(3 Pt 1):918-23.
1997: J G Timpone; D J Wright; N Li; Merrill J Egorin; M E Enama; J Mayers; GIORGIO GALETTO
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative.
AIDS research and human retroviruses 1997;13(4):305-15.
1997: Y Fujiwara; T Takahashi; M Yamakido; T Ohune; T Tsuya; Merrill J Egorin
Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Journal of the National Cancer Institute 1997;89(3):260-2.
1997: C M Kearns; Merrill J Egorin
Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy.
Seminars in oncology 1997;24(1 Suppl 2):S2-91-S2-96.
1997: Y Li; Alexander D. Mackerell; Merrill J Egorin; Michael F Ballesteros; DM Rosen; Y Y Wu; D A Blamble; PS Callery
Comparative molecular field analysis-based predictive model of structure-function relationships of polyamine transport inhibitors in L1210 cells.
Cancer research 1997;57(2):234-9.
1997: Merrill J Egorin; DM Rosen; S E Benjamin; PS Callery; DL Sentz; Julie L Eiseman
In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene.
Cancer chemotherapy and pharmacology 1997;41(1):9-14.
1997: BA Conley; Merrill J Egorin; R Sridhara; R Finley; Ramzi K Hemady; Suhlan Wu; Nancy Tait; David A Van Echo
Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics.
Cancer chemotherapy and pharmacology 1997;39(4):291-9.
1996: Michael Glantz; Hak Choy; Wallace Akerley; C M Kearns; Merrill J Egorin; C Harker Rhodes; Bernard F Cole
Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.
Seminars in oncology 1996;23(6 Suppl 16):128-35.
1996: Michael Glantz; Hak Choy; C M Kearns; Bernard F Cole; P Mills; Eleanor G Zuhowski; S Saris; C Harker Rhodes; Edward G Stopa; Merrill J Egorin
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):600-9.
1996: M S Simberkoff; P M Hartigan; J D Hamilton; P L Day; G R Diamond; Gordon M Dickinson; George L Drusano; Merrill J Egorin; W L George; F M Gordin; C A Hawkes; P C Jensen; N G Kilmas; A M Labriola; William A O'Brien; C N Oster; K J Weinhold; Nelda P Wray; S B Pazner
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(2):142-50.
1996: Y Li; Julie L Eiseman; DL Sentz; F A Rogers; S S Pan; L T Hu; Merrill J Egorin; PS Callery
Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane.
Journal of medicinal chemistry 1996;39(1):339-41.
1996: Merrill J Egorin; DL Sentz; DM Rosen; M F Ballesteros; C M Kearns; PS Callery; Julie L Eiseman
Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii.
Cancer chemotherapy and pharmacology 1996;39(1-2):51-60.
1996: A M Hussein; William P Petros; Maureen Ross; James J Vredenburgh; M L Affrontil; R B Jones; E J Shpall; P Rubin; MA Elkordy; Colleen Gilbert; C Gupton; Merrill J Egorin; John Soper; Andrew Berchuck; D Clarke-Person; D A Berry; William P Peters
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 1996;37(6):561-8.
1996: Julie L Eiseman; Zhi-Min Yuan; Natalie D. Eddington; DL Sentz; PS Callery; Merrill J Egorin
Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice.
Cancer chemotherapy and pharmacology 1996;38(1):13-20.
1996: D I Jodrell; Lilian S Murray; J Hawtof; Martin A Graham; Merrill J Egorin
A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941.
Cancer chemotherapy and pharmacology 1996;37(4):356-62.
1995: R Sridhara; Mario A Eisenberger; Victoria Sinibaldi; L M Reyno; Merrill J Egorin
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2944-53.
1995: Michael Glantz; Hak Choy; C M Kearns; Wallace Akerley; Merrill J Egorin
Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions.
Seminars in oncology 1995;22(5 Suppl 12):26-32.
1995: Joseph Aisner; Chandra P Belani; C Kearns; BA Conley; D Hiponia; C Engstrom; Eleanor G Zuhowski; Merrill J Egorin
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
Seminars in oncology 1995;22(5 Suppl 12):17-21.
1995: L M Reyno; Merrill J Egorin; Mario A Eisenberger; Victoria Sinibaldi; Eleanor G Zuhowski; R Sridhara
Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2187-95.
1995: Michael Glantz; Hak Choy; C M Kearns; P C Mills; L U Wahlberg; Eleanor G Zuhowski; P Calabresi; Merrill J Egorin
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.
Journal of the National Cancer Institute 1995;87(14):1077-81.
1995: C M Kearns; Luca Gianni; Merrill J Egorin
Paclitaxel pharmacokinetics and pharmacodynamics.
Seminars in oncology 1995;22(3 Suppl 6):16-23.
1995: Merrill J Egorin
Further refinement of carboplatin dosing.
Journal of the National Cancer Institute 1995;87(8):555-7.
1995: K Erkmen; Merrill J Egorin; L M Reyno; R Morgan; James Doroshow
Effects of storage on the binding of carboplatin to plasma proteins.
Cancer chemotherapy and pharmacology 1995;35(3):254-6.
1995: Luca Gianni; C M Kearns; A Giani; Giuseppe Capri; L Viganó; A Lacatelli; Gianni Bonadonna; Merrill J Egorin
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):180-90.
1995: BA Conley; S O'Hara; Suhlan Wu; T J Melink; H Parnes; E Pardoe; Merrill J Egorin; David A Van Echo
Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics.
Cancer chemotherapy and pharmacology 1995;37(1-2):139-49.
1994: M J Chang; Wei-Dong Yu; L M Reyno; Ruth A Modzelewski; Merrill J Egorin; K Erkmen; D R Vlock; P Furmanski; Candace S Johnson
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Cancer research 1994;54(20):5380-6.
1994: Merrill J Egorin; L M Reyno; R M Canetta; D I Jodrell; kenneth d swenerton; J L Pater; J N Burroughs; M J Novak; R Sridhara
Modeling toxicity and response in carboplatin-based combination chemotherapy.
Seminars in oncology 1994;21(5 Suppl 12):7-19.
1994: Zhi-Min Yuan; DM Rosen; Merrill J Egorin; PS Callery
Cytotoxic activity of N1- and N8-aziridinyl analogs of spermidine.
Biochemical pharmacology 1994;47(9):1587-92.
1994: Eleanor G Zuhowski; J C Gutheil; Merrill J Egorin
Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum.
Journal of chromatography. B, Biomedical applications 1994;655(1):147-52.
1994: Raymond W Klecker; CA Jamis-Dow; Merrill J Egorin; K Erkmen; R J Parker; R Stevens; Jerry M Collins
Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(2):254-8.
1994: Zhi-Min Yuan; Merrill J Egorin; DM Rosen; M A Simon; PS Callery
Cellular pharmacology of N1- and N8-aziridinyl analogues of spermidine.
Cancer research 1994;54(3):742-8.
1994: D I Jodrell; L M Reyno; R Sridhara; Mario A Eisenberger; Katherine Tkaczuk; Eleanor G Zuhowski; Victoria Sinibaldi; M J Novak; Merrill J Egorin
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):166-75.
1994: Julie L Eiseman; Natalie D. Eddington; James L Leslie; C MacAuley; DL Sentz; M Zuhowski; J M Kujawa; D Young; Merrill J Egorin
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice.
Cancer chemotherapy and pharmacology 1994;34(6):465-71.
1993: James L Leslie; J M Kujawa; Natalie D. Eddington; Merrill J Egorin; Julie L Eiseman
Stability problems with taxol in mouse plasma during analysis by liquid chromatography.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1349-52.
1993: Stuart M Lichtman; M J Ratain; David A Van Echo; Gary Rosner; Merrill J Egorin; Daniel R Budman; N J Vogelzang; Larry Norton; R L Schilsky
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Journal of the National Cancer Institute 1993;85(16):1319-26.
1993: L M Reyno; Merrill J Egorin; R M Canetta; D I Jodrell; kenneth d swenerton; J L Pater; J N Burroughs; M J Novak; R Sridhara
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1156-64.
1993: Samuel N Heyman; Katherine C Spokes; Merrill J Egorin; F H Epstein
Glycine reduces early renal parenchymal uptake of cisplatin.
Kidney international 1993;43(6):1226-8.
1993: Mario A Eisenberger; L M Reyno; D I Jodrell; Victoria Sinibaldi; Katherine Tkaczuk; R Sridhara; Eleanor G Zuhowski; Mark H Lowitt; Stephen C Jacobs; Merrill J Egorin
Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Journal of the National Cancer Institute 1993;85(8):611-21.
1993: A D Harpalani; S W Snyder; B Subramanyam; Merrill J Egorin; PS Callery
Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysis.
Cancer research 1993;53(4):766-71.
1993: Merrill J Egorin
Cancer pharmacology in the elderly.
Seminars in oncology 1993;20(1):43-9.
1993: BA Conley; Merrill J Egorin; M Y Whitacre; D C Carter; Eleanor G Zuhowski; David A Van Echo
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
Cancer chemotherapy and pharmacology 1993;33(2):107-12.
1993: David C Smith; D I Jodrell; Merrill J Egorin; Richard F Ambinder; Eleanor G Zuhowski; W Kreis; P G Ellis; D L Trump
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.
Cancer chemotherapy and pharmacology 1993;31(5):363-8.
1992: D I Jodrell; Merrill J Egorin; R M Canetta; Patricia Langenberg; E P Goldbloom; J N Burroughs; J L Goodlow; S Tan; E Wiltshaw
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):520-8.
1992: J D Hamilton; P M Hartigan; M S Simberkoff; P L Day; G R Diamond; Gordon M Dickinson; George L Drusano; Merrill J Egorin; W L George; F M Gordin
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
The New England journal of medicine 1992;326(7):437-43.
1992: Merrill J Egorin; D I Jodrell
Utility of individualized carboplatin dosing alone and in combination regimens.
Seminars in oncology 1992;19(1 Suppl 2):132-8.
1992: Everett E Vokes; J A Moormeier; Mark J Ratain; Merrill J Egorin; Daniel J Haraf; R Mick; Ralph R Weichselbaum
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Cancer chemotherapy and pharmacology 1992;29(3):178-84.
1992: Howard I Scher; D I Jodrell; J M Iversen; T Curley; W Tong; Merrill J Egorin; A Forrest
Use of adaptive control with feedback to individualize suramin dosing.
Cancer research 1992;52(1):64-70.
1992: M E Mortensen; A J Cecalupo; Warren D Lo; Merrill J Egorin; R Batley
Inadvertent intrathecal injection of daunorubicin with fatal outcome.
Medical and pediatric oncology 1992;20(3):249-53.
1992: S M Musser; S S Pan; Merrill J Egorin; D J Kyle; PS Callery
Alkylation of DNA with aziridine produced during the hydrolysis of N,N',N''-triethylenethiophosphoramide.
Chemical research in toxicology 1992;5(1):95-9.
1992: BA Conley; Merrill J Egorin; Victoria Sinibaldi; G Sewack; C Kloc; L Roberts; Eleanor G Zuhowski; A Forrest; David A Van Echo
Approaches to optimal dosing of hexamethylene bisacetamide.
Cancer chemotherapy and pharmacology 1992;31(1):37-45.
1991: D L Trump; Merrill J Egorin; A Forrest; James Willson; S Remick; K D Tutsch
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(11):2027-35.
1991: S W Snyder; Merrill J Egorin; PS Callery
Induction of human leukemia cell differentiation by regiospecifically acetylated spermidines.
Biochemical and biophysical research communications 1991;180(2):591-6.
1991: P F Dodion; D de Valeriola; N Crespeigne; J D Kantrowitz; M Piccart; F Wery; Joseph Kerger; Merrill J Egorin; A Forrest; N R Bachur
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(8):589-96.
1991: N A Cohen; Merrill J Egorin; S W Snyder; Bimal H Ashar; B E Wietharn; S S Pan; Douglas Ross; J Hilton
Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA.
Cancer research 1991;51(16):4360-6.
1991: Samuel N Heyman; seymour rosen; P Silva; Katherine C Spokes; Merrill J Egorin; F H Epstein
Protective action of glycine in cisplatin nephrotoxicity.
Kidney international 1991;40(2):273-9.
1991: BA Conley; G F Sewack; Merrill J Egorin; B Subramanyam; John G Page; C K Grieshaber
The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
Cancer chemotherapy and pharmacology 1991;28(1):33-8.
1991: D L de Valeriola; Douglas Ross; A Forrest; D P Cuddy; Merrill J Egorin
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.
Cancer chemotherapy and pharmacology 1991;29(2):133-40.
1990: BA Conley; Merrill J Egorin; Victoria Sinibaldi; David A Van Echo
Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.
Investigational new drugs 1990;8(4):365-7.
1990: Mark J Ratain; Richard L Schilsky; BA Conley; Merrill J Egorin
Pharmacodynamics in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1739-53.
1990: S R Gitterman; George L Drusano; Merrill J Egorin; HC Standiford
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.
Clinical pharmacology and therapeutics 1990;48(2):161-7.
1990: Merrill J Egorin; S W Snyder; B E Wietharn
Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells.
Cancer research 1990;50(14):4322-7.
1990: Merrill J Egorin; S W Snyder
Characterization of nonexchangeable radioactivity in L1210 cells incubated with [14C]thiotepa: labeling of phosphatidylethanolamine.
Cancer research 1990;50(13):4044-9.
1990: Merrill J Egorin
Phase I trials: a strategy of ongoing refinement.
Journal of the National Cancer Institute 1990;82(6):446-7.
1990: Merrill J Egorin; S W Snyder; S S Pan; C Daly
Cellular transport and accumulation of thiotepa.
Seminars in oncology 1990;17(1 Suppl 3):7-17.
1990: S W Snyder; Merrill J Egorin; Eleanor G Zuhowski; E C Schimpff; PS Callery
Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexane.
Cancer communications 1990;2(7):231-6.
1989: Chandra P Belani; Merrill J Egorin; J S Abrams; D Hiponia; Mario A Eisenberger; Joseph Aisner; David A Van Echo
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1896-902.
1989: Merrill J Egorin; S W Snyder; S S Pan; C Daly
Cellular transport and accumulation of thiotepa in murine, human, and avian cells.
Cancer research 1989;49(20):5611-7.
1989: M J Stone; G Klintmalm; D Polter; B Husberg; Merrill J Egorin
Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma.
Transplantation 1989;48(2):344-7.
1989: B Subramanyam; PS Callery; Merrill J Egorin; S W Snyder; BA Conley
An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(4):398-401.
1989: BA Conley; A Forrest; Merrill J Egorin; Eleanor G Zuhowski; Victoria Sinibaldi; David A Van Echo
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Cancer research 1989;49(12):3436-40.
1989: Merrill J Egorin; A Forrest; Chandra P Belani; M J Ratain; J S Abrams; David A Van Echo
A limited sampling strategy for cyclophosphamide pharmacokinetics.
Cancer research 1989;49(11):3129-33.
1989: David A Van Echo; Merrill J Egorin; Joseph Aisner
The pharmacology of carboplatin.
Seminars in oncology 1989;16(2 Suppl 5):1-6.
1989: T D Horn; R A Beveridge; Merrill J Egorin; M D Abeloff; A F Hood
Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation.
Archives of dermatology 1989;125(4):524-7.
1989: B Subramanyam; PS Callery; L A Geelhaar; Merrill J Egorin
A cyclic imine intermediate in the in vitro metabolic conversion of 1,6-diaminohexane to 6-aminohexanoic acid and caprolactam.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(1):33-42.
1989: Jacob Lokich; Merrill J Egorin; B E Cohen; MM Bern; T E Zipoli; C Moore
A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion.
Cancer 1989;63(1):46-50.
1989: Scott Wadler; Merrill J Egorin; E G Zuhowski; L Tortorello; K Salva; Carolyn D Runowicz; Peter H Wiernik
Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):132-9.
1988: B Miller; T Tenenholz; Merrill J Egorin; G Sosnovsky; N U Rao; Peter L Gutierrez
Cellular pharmacology of N,N',N''-triethylene thiophosphoramide.
Cancer letters 1988;41(2):157-68.
1988: S W Snyder; Merrill J Egorin; L A Geelhaar; Anne W Hamburger; PS Callery
Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide.
Cancer research 1988;48(13):3613-6.
1988: S P Ackland; K E Choi; Mark J Ratain; Merrill J Egorin; Stephanie F Williams; J A Sinkule; Jacob Bitran
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(7):1192-6.
1988: Merrill J Egorin; S W Snyder; A S Cohen; Eleanor G Zuhowski; B Subramanyam; PS Callery
Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cells.
Cancer research 1988;48(7):1712-6.
1988: Edward J Lee; Merrill J Egorin; David A Van Echo; A E Cohen; N Tait; Charles Alan Schiffer
Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia.
Journal of the National Cancer Institute 1988;80(2):131-5.
1988: BA Conley; Merrill J Egorin; Eleanor G Zuhowski; Victoria Sinibaldi; D E Peterson
Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.
Cancer chemotherapy and pharmacology 1988;22(1):65-8.
1988: BA Conley; PS Callery; Merrill J Egorin; B Subramanyam; L A Geelhaar; S S Pan
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
Life sciences 1988;43(9):793-800.
1988: Miriam C Poirier; Merrill J Egorin; A M Fichtinger-Schepman; Stuart H Yuspa; Eddie Reed
DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
IARC scientific publications 1988;(89):313-20.
1987: Merrill J Egorin; Eleanor G Zuhowski; A S Cohen; L A Geelhaar; PS Callery; David A Van Echo
Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
Cancer research 1987;47(22):6142-6.
1987: Merrill J Egorin; BA Conley; A Forrest; Eleanor G Zuhowski; Victoria Sinibaldi; David A Van Echo
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Cancer research 1987;47(22):6104-10.
1987: E H Oldfield; W C Clark; R L Dedrick; Merrill J Egorin; H A Austin; H D DeVroom; K M Joyce; J L Doppman
Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage.
Cancer research 1987;47(7):1962-7.
1987: Merrill J Egorin; Eleanor G Zuhowski; M S Nayar; PS Callery
Gas chromatographic analysis of metabolites of the cell differentiating agent hexamethylene bisacetamide.
Journal of chromatography 1987;415(1):148-55.
1987: Merrill J Egorin; L M Sigman; David A Van Echo; A Forrest; M Y Whitacre; Joseph Aisner
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Cancer research 1987;47(2):617-23.
1986: PS Callery; Merrill J Egorin; L A Geelhaar; M S Nayar
Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans.
Cancer research 1986;46(10):4900-3.
1986: B E Cohen; Merrill J Egorin; E A Kohlhepp; Joseph Aisner; Peter L Gutierrez
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Cancer treatment reports 1986;70(7):859-64.
1986: L M Sigman; David A Van Echo; Merrill J Egorin; M Y Whitacre; Joseph Aisner
Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Cancer treatment reports 1986;70(6):721-5.
1986: Merrill J Egorin; David A Van Echo; M Y Whitacre; A Forrest; L M Sigman; K L Engisch; Joseph Aisner
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Cancer research 1986;46(3):1513-20.
1986: Edward J Lee; David A Van Echo; Merrill J Egorin; M S Nayar; P Shulman; Charles Alan Schiffer
Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia.
Blood 1986;67(1):182-7.
1986: N S Tchekmedyian; Merrill J Egorin; B E Cohen; Richard S. Kaplan; E Poplin; Joseph Aisner
Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
Cancer chemotherapy and pharmacology 1986;18(1):33-8.
1985: P C Egan; M E Costanza; P Dodion; Merrill J Egorin; N R Bachur
Doxorubicin and cisplatin excretion into human milk.
Cancer treatment reports 1985;69(12):1387-89.
1985: Merrill J Egorin; David A Van Echo; E A Olman; M Y Whitacre; A Forrest; Joseph Aisner
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.
Cancer research 1985;45(12 Pt 1):6502-6.
1985: P Dodion; Merrill J Egorin; K L Engisch; N R Bachur
Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Cancer research 1985;45(11 Pt 1):5352-7.
1985: Merrill J Egorin; B E Cohen; E A Kohlhepp; Peter L Gutierrez
Gas-liquid chromatographic analysis of N,N',N''-triethylene thiophosphoramide and N,N',N''-triethylene phosphoramide in biological samples.
Journal of chromatography 1985;343(1):196-202.
1985: Peter L Gutierrez; Merrill J Egorin; T A Davis; N R Bachur
Effects of ascorbic acid on biologically obtained diaziquone free radicals.
Biochemical pharmacology 1985;34(13):2394-7.
1985: Peter L Gutierrez; B M Fox; M M Mossoba; Merrill J Egorin; H Nakazawa; N R Bachur
Electron spin resonance of electrochemically generated free radicals from diaziquone and its derivatives.
Biophysical chemistry 1985;22(1-2):115-23.
1985: Peter L Gutierrez; Merrill J Egorin; B M Fox; R Friedman; N R Bachur
Cellular activation of diaziquone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone] to its free radical species.
Biochemical pharmacology 1985;34(9):1449-55.
1985: Merrill J Egorin; B M Fox; J F Spiegel; Peter L Gutierrez; R D Friedman; N R Bachur
Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).
Cancer research 1985;45(3):992-9.
1985: J M Jones; E A Olman; Merrill J Egorin; Joseph Aisner
A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide.
Cancer chemotherapy and pharmacology 1985;14(2):172-4.
1985: P Dodion; Merrill J Egorin; C E Riggs; T A Ferraro; J M Tamburini; N R Bachur
Comparative murine metabolism and disposition of class II anthracycline antibiotics.
Cancer chemotherapy and pharmacology 1985;15(2):153-60.
1985: Peter L Gutierrez; B E Cohen; G Sosnovsky; T A Davis; Merrill J Egorin
On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT).
Cancer chemotherapy and pharmacology 1985;15(3):185-91.
1984: Merrill J Egorin; David A Van Echo; S J Tipping; E A Olman; M Y Whitacre; B W Thompson; Joseph Aisner
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Cancer research 1984;44(11):5432-8.
1984: Merrill J Egorin; S R Akman; Peter L Gutierrez
Plasma pharmacokinetics and tissue distribution of thiotepa in mice.
Cancer treatment reports 1984;68(10):1265-8.
1984: B E Cohen; Merrill J Egorin; M S Nayar; Peter L Gutierrez
Effects of pH and temperature on the stability and decomposition of N,N'N"-triethylenethiophosphoramide in urine and buffer.
Cancer research 1984;44(10):4312-6.
1984: David A Van Echo; Merrill J Egorin; M Y Whitacre; E A Olman; Joseph Aisner
Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.
Cancer treatment reports 1984;68(9):1103-14.
1984: H Nakazawa; C E Riggs; Merrill J Egorin; S M Redwood; N R Bachur; R Bhatnagar; Y Ito
Continuous extraction of urinary anthracycline antitumor antibiotics with the horizontal flow-through coil planet centrifuge.
Journal of chromatography 1984;307(2):323-33.
1984: Merrill J Egorin; E H Bellis; Michael Salcman; J M Collins; J F Spiegel; N R Bachur
The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
Journal of neurosurgery 1984;60(5):1005-13.
1984: P Dodion; B K Chang; Merrill J Egorin; E A Olman; K L Engisch; N R Bachur
The disposition of the new anthracycline antibiotic, menogarol, in mice.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(3):365-70.
1984: P Dodion; Merrill J Egorin; J M Tamburini; C E Riggs; N R Bachur
The murine metabolism and disposition of marcellomycin.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(2):209-16.
1983: T S Kaye; Merrill J Egorin; C E Riggs; E A Olman; F T Chou; Michael Salcman
The plasma pharmacokinetics and tissue distribution of dimethyl sulfoxide in mice.
Life sciences 1983;33(13):1223-30.
1983: Merrill J Egorin; R E Clawson; L A Ross; R D Friedman; S D Reich; A Pollak; N R Bachur
Murine metabolism and disposition of iron:adriamycin complexes.
Cancer research 1983;43(7):3253-62.
1983: Merrill J Egorin; P A Andrews; H Nakazawa; N R Bachur
Purification and characterization of aclacinomycin A and its metabolites from human urine.
Drug metabolism and disposition: the biological fate of chemicals 1983;11(2):167-71.
1983: H Gerad; Merrill J Egorin; M Whitacre; David A Van Echo; Joseph Aisner
Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.
Cancer chemotherapy and pharmacology 1983;11(3):162-6.
1983: J Z Fuks; Merrill J Egorin; Joseph Aisner; David A Van Echo; S Ostrow; N R Bachur; P H Wiernik
Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma.
Cancer chemotherapy and pharmacology 1983;10(2):104-8.
1983: J F Spiegel; Merrill J Egorin; J M Collins; B D Lerner; N R Bachur
The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
Drug metabolism and disposition: the biological fate of chemicals 1983;11(1):41-6.
1982: Merrill J Egorin; Richard S. Kaplan; Michael Salcman; Joseph Aisner; M Colvin; P H Wiernik; N R Bachur
Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide.
Clinical pharmacology and therapeutics 1982;32(1):122-8.
1982: R L Felsted; GREGORY POKRYWKA; C Chen; Merrill J Egorin; N R Bachur
Radioimmunoassay and immunochemistry of Phaseolus vulgaris phytohemagglutinin: verification of isolectin subunit structures.
Archives of biochemistry and biophysics 1982;215(1):89-99.
1982: P A Andrews; Merrill J Egorin; M E May; N R Bachur
Reversed-phase high-performance liquid chromatography analysis of 6-thioguanine applicable to pharmacologic studies in humans.
Journal of chromatography 1982;227(1):83-91.
1982: P H Konits; Merrill J Egorin; David A Van Echo; Joseph Aisner; P A Andrews; M E May; N R Bachur; P H Wiernik
Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma.
Cancer chemotherapy and pharmacology 1982;8(2):199-203.
1982: Merrill J Egorin; David A Van Echo; B M Fox; M Whitacre; N R Bachur
Plasma kinetics of aclacinomycin A and its major metabolites in man.
Cancer chemotherapy and pharmacology 1982;8(1):41-6.
1981: C E Riggs; Merrill J Egorin; J Z Fuks; N Schnaper; P Duffey; O M Colvin; Joseph Aisner; P H Wiernik; N R Bachur
Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin.
Journal of clinical pharmacology 1981;21(8-9 Suppl):90S-98S.
1981: Merrill J Egorin; R E Clawson; L A Ross; F T Chou; P A Andrews; N R Bachur
Disposition and metabolism of adriamycin octanoylhydrazone (NSC 233853) in mice and rabbits.
Drug metabolism and disposition: the biological fate of chemicals 1981;9(3):240-5.
1981: R E Clawson; Merrill J Egorin; B M Fox; L A Ross; N R Bachur
Hyperthermic modification of cyclophosphamide metabolism in rat hepatic microsomes and liver slices.
Life sciences 1981;28(10):1133-7.
1981: J Z Fuks; Merrill J Egorin; Joseph Aisner; S S Ostrow; M E Klein; N R Bachur; M Colvin; P H Wiernik
Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics.
Cancer chemotherapy and pharmacology 1981;6(2):117-20.
1981: R L Felsted; J Li; GREGORY POKRYWKA; Merrill J Egorin; J Spiegel; R M Dale
Comparison of Phaseolus vulgaris cultivars on the basis of isolectin differences.
The International journal of biochemistry 1981;13(5):549-57.
1981: S Ostrow; Merrill J Egorin; D Hahn; S Markus; Joseph Aisner; P Chang; A LeRoy; N R Bachur; P H Wiernik
High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Cancer treatment reports 1981;65(1-2):73-8.
1980: Merrill J Egorin; R E Clawson; J L Cohen; L A Ross; N R Bachur
Cytofluorescence localization of anthracycline antibiotics.
Cancer research 1980;40(12):4669-76.
1980: S Ostrow; Merrill J Egorin; D Hahn; S Markus; A Leroy; P Chang; M Klein; N R Bachur; P H Wiernik
Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms.
Cancer 1980;46(8):1715-21.
1980: Merrill J Egorin; R E Clawson; L A Ross; F T Chou; P A Andrews; N R Bachur
Disposition and metabolism of N,N-dimethyldaunorubicin and N,N-dimethyladriamycin in rabbits and mice.
Drug metabolism and disposition: the biological fate of chemicals 1980;8(5):353-62.
1980: Merrill J Egorin; R E Clawson; L A Ross; N R Bachur
Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin.
Cancer research 1980;40(6):1928-33.
1980: S Ostrow; Merrill J Egorin; Joseph Aisner; N Bachur; P H Wiernik
High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
Cancer clinical trials 1980;3(1):23-7.
1980: A F LeRoy; M Wehling; P Gormley; Merrill J Egorin; S Ostrow; N Bachur; P Wiernik
Quantitative changes in cis-dichlorodiammineplatinum(II) speciation in excreted urine with time after iv infusion in man: methods of analysis, preliminary studies, and clinical results.
Cancer treatment reports 1980;64(1):123-32.
1979: Merrill J Egorin; R E Clawson; L A Ross; N M Schlossberger; N R Bachur
Cellular accumulation and disposition of aclacinomycin A.
Cancer research 1979;39(11):4396-400.
1979: Merrill J Egorin; R E Clawson; J L Cohen; L A Ross; N R Bachur
Cellular pharmacology of 7(R)-O-methylnogarol: a new anticancer agent.
The Journal of pharmacology and experimental therapeutics 1979;210(2):229-36.
1979: Merrill J Egorin; S Z Bachur; R L Felsted; R D Leavitt; N R Bachur
Phaseolus vulgaris isolectin binding to human erythrocytes.
The Journal of biological chemistry 1979;254(3):894-8.
1978: Merrill J Egorin; F Litvin; R L Felsted; N R Bachur
Phytohemagglutinin isolectin stimulation of human lympocytes cultured in serum free medium.
Life sciences 1978;23(3):237-45.
1978: Merrill J Egorin; R N Odders; F T Sanel; R L Felsted; N R Bachur
Inhibitory effects of phytohemagglutinin isolectins L4 and E4 on L1210 cells.
Cancer research 1978;38(6):1677-87.
1978: Merrill J Egorin; R L Felsted; N R Bachur
Salicylate effects on the response of human lymphocytes to phytohemagglutinin isolectins.
Clinical immunology and immunopathology 1978;10(1):1-10.
1977: R L Felsted; Merrill J Egorin; R D Leavitt; N R Bachur
Recombinations of subunits of Phaseolus vulgaris isolectins.
The Journal of biological chemistry 1977;252(9):2967-71.
1977: Merrill J Egorin; R L Felsted; N R Bachur
Phytohemagglutinin isolectin stimulation of glucose utilization by lymphocytes.
Life sciences 1977;20(2):351-7.
1976: Merrill J Egorin; D L Trump; C W Wainwright
Quinacrine ochronosis and rheumatoid arthritis.
JAMA : the journal of the American Medical Association 1976;236(4):385-6.
1974: Merrill J Egorin; R C Hildebrand; E F Cimino; N R Bachur
Cytofluorescence localization of adriamycin and daunorubicin.
Cancer research 1974;34(9):2243-5.
1973: J C Cradock; Merrill J Egorin; N R Bachur
Daunorubicin biliary excretion and metabolism in the rat.
Archives internationales de pharmacodynamie et de thérapie 1973;202(1):48-61.